Clinical Trials
88 trialsTesting Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Tianjin Medical University Cancer Institute and Hospital
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Hoosier Cancer Research Network
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Rutgers, The State University of New Jersey
NLCCRIT-LARC
Peking University People's Hospital
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
TRACER
Sixth Affiliated Hospital, Sun Yat-sen University
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Sun Yat-sen University
TORCH-R
Fudan University
RADIANCE
Goethe University
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Fudan University
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
Sun Yat-sen University
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
MEMORI
Technical University of Munich
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
M.D. Anderson Cancer Center
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients
Zhejiang Provincial People's Hospital
AMBITION
Osaka University
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Massachusetts General Hospital
FOLRT
Campus Bio-Medico University
Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer
Wuhan University
REVO
Fujian Cancer Hospital
NORMAL-R
Washington University School of Medicine
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
Hangzhou Cancer Hospital
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Hangzhou Cancer Hospital
Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
University Hospital Schleswig-Holstein
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
Brown University